OptimizeRx (OPRX) Projected to Post Quarterly Earnings on Thursday

Key Points

• OptimizeRx is expected to report Q3 2026 results after the market closes on November 5. Analysts forecast earnings of $0.18 per share and revenue of $21.19 million; the earnings call is scheduled for November 11 at 4:30 p.m. ET.
• The company’s previous quarter exceeded expectations, with EPS of $0.16 versus the $0.11 consensus and revenue of $20.50 million versus estimates of $20.20 million.
• Analysts maintain a generally positive view, with a consensus “Moderate Buy” rating and an average price target of $11.57, compared with the stock’s reported price of $9.30.

OptimizeRx (NASDAQ:OPRX - Get Free Report) is expected to announce its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of $0.18 per share and revenue of $21.19 million for the quarter. Interested persons may review the information on the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 4:30 PM ET.

OptimizeRx (NASDAQ:OPRX - Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The company reported $0.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.05. The company had revenue of $20.50 million for the quarter, compared to analyst estimates of $20.20 million. OptimizeRx had a net margin of 4.66% and a return on equity of 9.44%. On average, analysts expect OptimizeRx to post $0.49 EPS for the current fiscal year and $0.66 EPS for the next fiscal year.

OptimizeRx Stock Performance

Shares of OPRX stock opened at $9.30 on Thursday. The stock has a market capitalization of $175.21 million, a P/E ratio of 40.44 and a beta of 1.26. The company has a current ratio of 5.58, a quick ratio of 5.58 and a debt-to-equity ratio of 0.14. The firm's 50 day moving average is $8.15 and its 200 day moving average is $7.40. OptimizeRx has a 12 month low of $4.54 and a 12 month high of $21.56.

Analyst Ratings Changes

A number of research analysts have weighed in on OPRX shares. Citigroup reaffirmed a "market outperform" rating on shares of OptimizeRx in a report on Tuesday. Stifel Nicolaus set a $12.00 price target on shares of OptimizeRx in a report on Thursday, August 13th. UBS Group set a $11.00 price target on shares of OptimizeRx in a report on Friday, August 14th. Wall Street Zen lowered shares of OptimizeRx from a "strong-buy" rating to a "buy" rating in a research report on Monday, July 20th. Finally, Citizens Jmp boosted their price objective on shares of OptimizeRx from $9.00 to $11.00 and gave the company a "market outperform" rating in a research note on Friday, August 14th. Six investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $11.57.

About OptimizeRx

OptimizeRx Corporation NASDAQ: OPRX is a digital health and life sciences technology company that helps pharmaceutical and biotechnology companies connect with healthcare professionals and patients. Its platform supports prescription-related communications, treatment access, affordability, adherence and patient engagement throughout the medication journey.

The company provides solutions that can be integrated into electronic health records and other healthcare workflows. Its offerings include point-of-care messaging for healthcare professionals, patient support and savings programs, medication access tools, and data and analytics services designed to help life sciences companies communicate with relevant audiences and understand engagement.

OptimizeRx was founded in 2006 and has primarily served the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.